Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA >20ng/mL or Gleason 8-10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6, respectively. Five-year bRFS and cRFS were 73 and 86 respectively. AD was a significant predictor of bRFS (P = 0.001) and cRFS (P = 0.01). Conclusion. High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity. Copyright © 2012 Valérie Fonteyne et al.
Fonteyne, V., Lumen, N., Villeirs, G., Ost, P., & De Meerleer, G. (2012). Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Advances in Urology. https://doi.org/10.1155/2012/368528